It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Senescent cells accumulate in human tissues during ageing and contribute to age-related pathologies. The mechanisms responsible for their accumulation are unclear. Here we show that senescent dermal fibroblasts express the non-classical MHC molecule HLA-E, which interacts with the inhibitory receptor NKG2A expressed by NK and highly differentiated CD8+ T cells to inhibit immune responses against senescent cells. HLA-E expression is induced by senescence-associated secretary phenotype-related pro-inflammatory cytokines, and is regulated by p38 MAP kinase signalling in vitro. Consistently, HLA-E expression is increased on senescent cells in human skin sections from old individuals, when compared with those from young, and in human melanocytic nevi relative to normal skin. Lastly, blocking the interaction between HLA-E and NKG2A boosts immune responses against senescent cells in vitro. We thus propose that increased HLA-E expression contributes to persistence of senescent cells in tissues, thereby suggesting a new strategy for eliminating senescent cells during ageing.
Senescent cells increase with ageing and may cause inflammatory conditions, but how this accumulation is mediated is still unclear. Here the authors show that senescent cells express HLA-E to suppress NKG2A-mediated natural killer and CD8 T cell activation to avoid targeted elimination, while blocking NKG2A helps promote immunity against senescent cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University College London, Division of Infection and Immunity, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
2 Great Ormond Street Hospital for Children, University College London, Institute of Histopathology, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
3 Great Ormond Street Hospital for Children, University College London, Paediatric Dermatology Department, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
4 Buck Institute for Research on Aging, Novato, USA (GRID:grid.272799.0) (ISNI:0000 0000 8687 5377)
5 Institute for Cell and Molecular Biosciences & Newcastle University Institute for Ageing, Newcastle upon Tyne, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212); Mayo Clinic, Department of Physiology and Biomedical Engineering, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
6 Faculty of Health and Life Sciences, Northumbria University, Department of Applied Sciences, Newcastle Upon Tyne, UK (GRID:grid.42629.3b) (ISNI:0000000121965555)
7 Buck Institute for Research on Aging, Novato, USA (GRID:grid.272799.0) (ISNI:0000 0000 8687 5377); Lawrence Berkeley National Laboratory, Berkeley, USA (GRID:grid.184769.5) (ISNI:0000 0001 2231 4551)